Company Overview and News
REUTERS: Smiths Group Plc expects a 2 percent drop in full-year revenue at its medical unit, hurt by some products losing certifications under a new regulation and the loss of two contracts in the United States, it said on Wednesday.
SMIN SMGZY SMGKF ICUI
SAN CLEMENTE, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its second quarter 2018 earnings release and conference call.
Intrexon Corp. (NYSE:XON) has 183 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 111,162,559 shares. Largest shareholders include Third Security, LLC, Iridian Asset Management Llc/ct, Vanguard Group Inc, FMR LLC / Fidelity, Lmm Llc, State Street Corp, First Trust Advisors Lp, Morgan Stanley, BlackRock Inc.
STT STT.PRC XON STT.PRE STT.PRD STT.PRG MS.PRE VRX MS.PRF MS.PRG ISRG MS.PRA PGNX BLK MS.PRI BSX MS.PRK ICUI MS SLXP MZOR
Investors focused on the Medical space have likely heard of ICU Medical (ICUI - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ICU Medical: "This is actually kind of an interesting company. Look, when we get, whether it be AtriCure, whether it be this, when we get these medical device companies, they tend to be big winners and they have less downside. Look at Boston Scientific, Intuitive Surgical, Mazor Robotics. They all work. That's why we're behind that group. And don't forget: we think the least expensive is Abbott Labs, but we also like Dexcom.
BSX XON ICUI ISRG MZOR
(Reuters) - British engineering firm Smiths Group Plc (SMIN.L) and U.S.-based ICU Medical Inc (ICUI.O) are in talks about a merger of their medical device businesses, a person familiar with the discussions told Reuters.
SMIN SMGZY SMGKF ICUI
Document UNITED STATES
Chicago, IL – May 16, 2018 - Stocks in this week’s article include: Medifast, Inc. (MED - Free Report) , Myriad Genetics, Inc. (MYGN - Free Report) , ICU Medical, Inc. (ICUI - Free Report) , Ellie Mae, Inc. (ELLI - Free Report) and UGI Corporation (UGI - Free Report) .
LOPE HD EAT UGI FIX ELLI BAX JOUT JEC MED DG MYGN CVRR ICUI PETS SWM ENVA NSIT
Following the crowd mindlessly, especially when it comes to investing, is not advisable. The common perception is that only risky stocks generate high returns. However, this strategy works well only when the market is bullish.
UGI MED MYGN ICUI ELLI
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ICUI / ICU Medical, Inc. on message board site Silicon Investor.
|ICUI -- disposable medical connection system||ICU Medical, Incorporated|
as of ET